THE PULMONARY ABNORMALITIES IN MYXEDEMA

Por Wilson, William R., Bedell, George N.
Publicado em 1960

Rapid Development of Bilateral Internal Carotid Artery Aneurysm from Sphenoid Sinus Aspergillosis

Por Wilson, William R., Hawrych, Andrew, Olan, Wayne
Publicado em 1998

Pharmacodynamic Effects of Beta-Adrenergic Receptor Blockade in Patients with Hyperthyroidism

Por Wilson, William R., Theilen, Ernest O., Fletcher, Fred W.
Publicado em 1964

Pulmonary Function in Obese Persons

Por Bedell, George N., Wilson, William R., Seebohm, Paul M.
Publicado em 1958

Targeting hypoxia in the leukemia microenvironment

Por Benito, Juliana, Zeng, Zhihong, Konopleva, Marina, Wilson, William R
Publicado em 2013

Hypoxia-activated prodrugs: paths forward in the era of personalised medicine

Por Hunter, Francis W, Wouters, Bradly G, Wilson, William R
Publicado no Br J Cancer (2016)

Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling

Por Foehrenbacher, Annika, Secomb, Timothy W., Wilson, William R., Hicks, Kevin O.
Publicado em 2013

DNA Adduct Profiles Predict in Vitro Cell Viability after Treatment with the Experimental Anticancer Prodrug PR104A

Por Stornetta, Alessia, Villalta, Peter W., Gossner, Frederike, Wilson, William R., Balbo, Silvia, Sturla, Shana J.
Publicado no Chem Res Toxicol (2017)

Effects of triiodothyronine-induced hypermetabolism on factor VIII and fibrinogen in man

Por Hoak, John C., Wilson, William R., Warner, Emory D., Theilen, Ernest O., Fry, Glenna L., Benoit, Fred L.
Publicado em 1969

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

Por Amies Karen, Hill Andrew, Wilson William R, Gu Yongchuan, McKeage Mark J, Melink Teresa J, Jameson Michael B
Publicado em 2011-10-01

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

Por McKeage, Mark J, Gu, Yongchuan, Wilson, William R, Hill, Andrew, Amies, Karen, Melink, Teresa J, Jameson, Michael B
Publicado em 2011

The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104

Por Foehrenbacher, Annika, Patel, Kashyap, Abbattista, Maria R., Guise, Chris P., Secomb, Timothy W., Wilson, William R., Hicks, Kevin O.
Publicado em 2013

Zinc Finger Nuclease Knock-out of NADPH:Cytochrome P450 Oxidoreductase (POR) in Human Tumor Cell Lines Demonstrates That Hypoxia-activated Prodrugs Differ in POR Dependence

Por Su, Jiechuang, Gu, Yongchuan, Pruijn, Frederik B., Smaill, Jeff B., Patterson, Adam V., Guise, Christopher P., Wilson, William R.
Publicado em 2013

Zinc Finger Nuclease Mediated Knockout of ADP-Dependent Glucokinase in Cancer Cell Lines: Effects on Cell Survival and Mitochondrial Oxidative Metabolism

Por Richter, Susan, Morrison, Shona, Connor, Tim, Su, Jiechuang, Print, Cristin G., Ronimus, Ron S., McGee, Sean L., Wilson, William R.
Publicado em 2013

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

Por McKeage Mark J, Jameson Michael B, Ramanathan Ramesh K, Rajendran Joseph, Gu Yongchuan, Wilson William R, Melink Teresa J, Tchekmedyian N
Publicado em 2012-10-01

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

Por McKeage, Mark J, Jameson, Michael B, Ramanathan, Ramesh K, Rajendran, Joseph, Gu, Yongchuan, Wilson, William R, Melink, Teresa J, Tchekmedyian, N Simon
Publicado em 2012

Effectiveness of Combined Modality Radiotherapy of Orthotopic Human Squamous Cell Carcinomas in Nu/Nu Mice Using Cetuximab, Tirapazamine and MnSOD-Plasmid Liposome Gene Therapy

Por EPPERLY, MICHAEL W., LAI, STEPHEN Y., KANAI, ANTHONY J., MASON, NEAL, LOPRESI, BRIAN, DIXON, TRACEY, FRANICOLA, DARCY, NIU, YUNYUN, WILSON, WILLIAM R., GREENBERGER, JOEL S.
Publicado em 2010

(18)F-EF5 PET Imaging as an Early Response Biomarker for the Hypoxia-Activated Prodrug SN30000 Combined with Radiation Treatment in a Non–Small Cell Lung Cancer Xenograft Model

Por Chitneni, Satish K., Bida, Gerald T., Yuan, Hong, Palmer, Gregory M., Hay, Michael P., Melcher, Thorsten, Wilson, William R., Zalutsky, Michael R., Dewhirst, Mark W.
Publicado em 2013

Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma

Por Abbattista, Maria R, Jamieson, Stephen M F, Gu, Yongchuan, Nickel, Jennifer E, Pullen, Susan M, Patterson, Adam V, Wilson, William R, Guise, Christopher P
Publicado no Cancer Biol Ther (2015)

Tricyclic [1,2,4]Triazine 1,4-Dioxides As Hypoxia Selective Cytotoxins

Por Hay, Michael P., Hicks, Kevin O., Pchalek, Karin, Lee, Ho H., Blaser, Adrian, Pruijn, Frederik B., Anderson, Robert F., Shinde, Sujata S., Wilson, William R., Denny, William A.
Publicado em 2008